bioAffinity Closes $4M Registered Direct Offering and Suspends ATM
BIAF is trading near its 52-week low of $4.56 (0.2% below the low) on light trading volume (0.2× avg).
Summary
bioAffinity closed a $4M registered direct offering at $6.122/share with pre-funded warrants and a concurrent private placement of warrants for up to 980,072 shares. The company also suspended its ATM program.
Key Events · Financing and Capital Events · BIAF
-
$4M Registered Direct Offering Closed
Closed October 9, 2026: 116,545 shares of common stock at $6.122/share and pre-funded warrants for up to 536,836 shares at $6.115/warrant, with gross proceeds of approximately $4 million.
-
Concurrent Private Placement of Warrants
Warrants to purchase up to 980,072 shares at $6.122/share, exercisable after stockholder approval and expiring five years from that date. Placement agent WallachBeth received a 7.5% cash fee, $70,000 expense reimbursement, and warrants for 19,602 shares.
-
ATM Program Suspended
Effective October 8, 2026, the company suspended the prospectus supplement for its May 2025 ATM sales agreement. No further ATM sales will occur unless a new prospectus supplement is filed.
-
Survival Financing Amid Going Concern
The raise comes as the company's last 10-Q disclosed a going-concern warning and a cash runway expected to end this month. Proceeds are earmarked for working capital and CyPath Lung sales support.
Analysis · BIAF · Industrial Applications And Services
bioAffinity closed a $4 million registered direct offering priced at $6.122 per share, with pre-funded warrants and a concurrent private placement of warrants to purchase up to 980,072 shares. The company also suspended its existing ATM prospectus supplement, halting further sales under that program. For a company with a going-concern warning and a cash runway that was expected to end this month, this capital raise is survival financing — it extends operations but adds substantial potential dilution through the warrants.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIAF was trading at $4.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $4.56 to $80.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.